Win Ratio Analysis of Edoxaban vs Dalteparin in Cancer-Associated VTE – JTH
Journal of Thrombosis and Haemostasis shared a post on LinkedIn about a recent article by Nick van Es et al, adding:
”The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE Cancer trial
Novel win ratio analysis comparing edoxaban versus dalteparin in cancer-associated VTE reveals no significant difference between treatments when evaluating hierarchically prioritized outcomes including mortality, recurrent events, and bleeding complications.”
Title: The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial
Authors: Nick van Es, Luuk J.J. Scheres, Kristen M. Sanfilippo, Harry Büller, Marc Carrier, Marcello Di Nisio, Michael Grosso, Renato D. Lopes, William F. McIntyre, Bjorn Redfors, Annelise Segers, Peter Verhamme, Jeffrey I. Weitz, Patrick M. Bossuyt, Deborah M. Siega
Read the Full Article on Journal of Thrombosis and Haemostasis.
Stay updated with Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation